Last reviewed · How we verify
Bosutinib capsule (bosutinib-capsule)
At a glance
| Generic name | bosutinib-capsule |
|---|---|
| Sponsor | Pfizer Inc. |
| Phase | FDA-approved |
| Annual revenue | 611 |
Approved indications
Common side effects
Key clinical trials
- A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP (PHASE3)
- Bioavailability of Bosutinib Administered as Capsule Contents Mixed With Applesauce or Yogurt Relative to Intact Capsules Under Fed Condition (PHASE1)
- Evaluation of the Relative Bioavailability of Bosutinib Capsules Under Fed Condition and Estimation of Food Effect on Orally Administered Bosutinib Capsule (PHASE1)
- Impact of Bosutinib on Safety, Tolerability, Biomarkers and Clinical Outcomes in Dementia With Lewy Bodies (PHASE2)
- Bioequivalence Study of Bosutinib Pediatric Capsule Relative to Commercial Tablet Under Fed Condition (PHASE1)
- Palatability (Taste) of Oral Formulations of Bosutinib (PHASE1)
- Study Evaluating SKI-606 (Bosutinib) In Japanese Subjects With Philadelphia Chromosome Positive Leukemias (PHASE2)
- Bioequivalence And Food Effect Study Of Bosutinib In Healthy Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
| SEC EDGAR | Revenue + earnings |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Bosutinib capsule CI brief — competitive landscape report
- Bosutinib capsule updates RSS · CI watch RSS
- Pfizer Inc. portfolio CI